Tour de Gymnáziá 2026
TOUR DE GYMNÁZIÁ 2026
Three days, five schools, the 8th edition, dozens of questions, hundreds of young people, and an extraordinary amount of hope.
Our CEO, Pavol Čekan, met with talented students who are genuinely interested in science, medicine, biology, research, and in understanding how an idea can become a real technology that helps patients.
He shared his personal journey — about the life of a scientist, studying and working abroad, returning home, successes as well as setbacks, because those are also an essential part of science. Together, we discussed cancer, research, and why it is worth persevering when you truly believe in something.
We were especially inspired by the number of thoughtful and insightful questions raised throughout the tour.
Slovakia is home to many bright and capable young people. They only need to see that science matters, that great things can be achieved from Slovakia, and that returning home after studying abroad can be the right decision.
We thank all schools, teachers, and especially the students for their energy, attention, and genuine interest. It was an honor to spend time with you.
Encounters like these always remind us that it is all worth it.
For science.
For young people.
For Slovakia.
About MultiplexDX
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter
